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ower-extremity peripheral artery disease (PAD) is on the rise and affects up to 200 million patients globally and >8 million in the United States. PAD incidence and prevalence are strongly age related, mounting to an absolute prevalence of >10% among patients in their 60s and 70s. It is well understood that PAD is the manifestation of systemic atherosclerosis and often associated with cigarette smoking, hypertension, and diabetes mellitus. Patients with vascular disease in multiple vascular beds (often called polyvascular) are likely at the highest risk for cardiovascular morbidity and mortality, but PAD alone is also an independent risk factor for cardiovascular events. 1 One of the most common comorbidities among patients with PAD is hypertension, with a prevalence ranging from 30% to 80% on the basis of age, sex, and systolic blood pressure (SBP) cutoffs.
2-4 Hypertension not only is associated with the development and progression of PAD but also confers an additional risk of cardiovascular morbidity and mortality, starting with an SBP as low as 110 mm Hg. 5 All patients with cardiovascular disease (including patients with PAD) should be treated for hypertension with the intent to reduce the number of fatal and nonfatal cardiovascular events. 6, 7 However, blood pressure management and control in PAD are poor. In an US-wide registry of patients with PAD, those with hypertension were less often treated (84% of newly diagnosed patients and 88% of patients with known PAD) compared with patients with other cardiovascular disease (95% on treatment). 8 In this issue of Circulation, Itoga and coauthors 9 tackle the major question of appropriate blood pressure targets in PAD and call into question some of the current recommendations for hypertension management in this complex patient population. Blood pressure treatment goals in patients with PAD need careful consideration given that lower blood pressures may exacerbate an already impaired oxygen delivery to limbs and exacerbate symptoms of PAD. The most recent American College of Cardiology/American Heart Association hypertension guidelines recommend lower blood pressure treatment targets for patients at high cardiovascular risk (goal <130/80 mm Hg). 7 Given a lack of prospective evidence in support of higher versus lower treatment targets from large clinical trials, the guidelines recommend treating patients with PAD the same way as patients with established cardiovascular disease, and the treatment target has historically been <130/80 mm Hg.
To date, the evidence for blood pressure treatment targets in patients with PAD is limited to small prospective studies and retrospective analyses of antihypertensive trials. A recent meta-analysis of small prospective studies indicated that antihypertensive treatment has not been associated with worsening symptoms and outcomes in PAD but may be associated with improved leg ischemia. 10 The ABCD trial (Appropriate Blood-Pressure Control in Diabetes) showed that in patients with diabetes mellitus and PAD, intensive blood pressure lowering to an average of 128/75 mm Hg was associated with a reduction of cardiovascular events. 11 Findings from the HOPE study (Heart Outcomes Prevention Evaluation) suggested that antihypertensive treatment in PAD reduces cardiovascular morbidity and mortality. 12 Beneficial effects on lowering blood pressure in a high-risk population extended beyond patients with clinical PAD to patients with subclinical PAD, defined as asymptomatic patients with abnormal ankle-brachial index testing. The recent SPRINT trial (Systolic Blood Pressure Intervention Trial) demonstrated that a more aggressive SBP target of ≤120 mm Hg among patients at high risk of cardiovascular events, which included patients with PAD, resulted in substantially lower rates of cardiovascular events and associated mortality. 13 A substudy of the SPRINT trial showed that although lower diastolic blood pressure (DBP) was associated with worse cardiovascular outcomes, there was no sign that the advantage of the intensive SBP lowering differed by baseline DBP.
14 The SPRINT trial, however, was limited by a small number of patients with PAD and PAD-related events, and a PADspecific analysis has not yet been published. Finally, a post hoc analysis of INVEST (International Verapamil-SR/ Trandolapril Study), which randomized hypertensive patients with comorbid PAD and coronary artery disease, showed that lower rates of all-cause death, nonfatal myocardial infarction, or stroke (improved outcomes) were observed in patients with an SBP of 135 to 145 mm Hg and a signal of harm with lower blood pressures only in the PAD population. 15 In light of this conflicting evidence, the present findings of a post hoc analysis of the ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) are thought-provoking and hypothesis-generating. 9 The authors investigated the association of SBP, DBP, and pulse pressure with PAD events in patients with hypertension and elevated cardiovascular risk. The ALLHAT trial was a randomized multicenter trial investigating various antihypertensive medications (chlorthalidone, amlodipine, lisinopril, and doxazosin), and the target blood pressure for all participants was set as <140/90 mm Hg. Blood pressure measurements during the study were completed in a systematic fashion with a manual sphygmomanometer, with follow-up blood pressure measurements being averaged (rather than using the lower or higher measurements). Unfortunately, patients with upper-extremity PAD (eg, subclavian artery stenosis) and the effects of lower arm pressures were not accounted for in the analysis. The outcomes of interest for the present analysis were lower-extremity PAD events and were defined as the first PAD-related hospitalization (with or without a revascularization procedure), PAD-related procedures (lowerextremity bypass, angioplasty, revascularization, or amputation), outpatient PAD medical treatment (as noted by the treating physician in a study questionnaire), or PAD-related death. The final analytical cohort included >33 000 patients.
The main finding of this study was a higher risk of lower-extremity PAD events in patients with an SBP <120 mm Hg compared with the reference group with SBPs of 120 to 129 mm Hg, who had the lowest rate of the primary outcome. Patients who had documented SBP <120 mm Hg during study follow-up (only 3% of the entire study cohort) had an adjusted hazard ratio of 1.26 (95% CI, 5-25; P=0.015). The J-shaped relationship between SBP and PAD events remained unchanged after adjustment for age and the presence of diabetes mellitus. Similarly, patients with a DBP <70 mm Hg (7% of entire population) were at greater risk for PAD events, and with lower DBP, the risk for PAD events increased. This post hoc analysis draws strength from the very large sample size and longitudinal blood pressure measurements during follow-up. Furthermore, the ALLHAT trial enrolled a relatively high-risk population even though the trial did not target patients with PAD. As a result, nearly 1500 patients experienced PAD events (5% of the trial population).
Despite the rigorous statistical approach and the unprecedented number of patients, this retrospective analysis has some important limitations. First and most important, the original trial did not independently determine PAD status at baseline, and the presence of baseline PAD was included in an "other atherosclerosis" category. Furthermore, there was no information on the severity of hemodynamic impairment (eg, ankle-brachial index values) in these patients at baseline or during the course of the study. Second, patients in the groups with the lowest blood pressures (SBP or DBP) during the trial were more likely to have coronary artery disease and other atherosclerosis, including PAD. Just as important, very few patients in the ALLHAT study had SBP or DBP in the lower categories. Finally, PAD events were secondary end points in the original trial and were reported by site investigators but did not undergo formal adjudication by an independent clinical end point classification group. Thus, uncertainty remains about who had baseline or incident lower-extremity PAD, the burden and severity of PAD that may affect the occurrence of limb events, and the substantial heterogeneity and lack of adjudication of the recorded PAD events.
In summary, the major takeaway from this analysis is that low blood pressure is associated with a higher risk of PAD events. Although this is not an entirely new finding, it is especially timely given the new SBP targets set by the American College of Cardiology/American Heart Association guidelines. 7 The new guidelines do not specify a low end of the target range and provide no specific guidance for patients with PAD. Because the prevalence of PAD and hypertension continues to rise and remains a major health problem, the question of the most efficacious and safe SBP and DBP targets for patients with PAD needs to be urgently addressed. Ideally, this will be accomplished by prospective clinical trials; however, multiple existing data sources are currently available to confirm or refute these findings. To add confidence to the current findings, data from these studies should include an accurate PAD phenotype, longitudinal blood pressure measurements, a complete trigger system to ascertain PAD events, and rigorous end point classification of limb events (Figure) . However, it needs to be stressed that the global problem resulting from underrecognized and undertreated hypertension supersedes the potential harm from overly aggressive blood pressure targets, and until confirmed, these findings should not distract from the overwhelming evidence that treating and reducing blood pressure in patients at risk for PAD improve clinical outcomes. Thus, patients with PAD should be treated to lower SBP targets (<120 mm Hg) until confirmatory studies have been completed. 
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